Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.
Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. The disease has a relapsing and remitting course that can, in severe instances, be life-threatening. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.
A recent, single-center, retrospective, case-control study reported on 40 patients with PV, treated at Duke University from 1999 to 2015, who required steroids plus conventional adjuvant therapy with agents such as mycophenolate mofetil, azathioprine, adalimumab, or infliximab (n = 27), or steroids and conventional therapy followed by rituximab (n = 13).
The group who received rituximab was able to reduce median monthly prednisone intake from pre-rituximab levels of 658.6 mg per month (interquartile range [IQR], 600.0-724.8) to 177.2 mg per month (IQR, 97.3-309.5) after starting rituximab.
There was no difference in monthly prednisone intake between the conventional therapy group and the rituximab group after treatment, but the patients who received conventional treatment only had significantly lower monthly prednisone intake (141 mg per month; IQR, 79.3-428.8) versus the pre-rituximab patients. There was no difference in the likelihood of being able to discontinue prednisone between the patient groups.
Additionally, patients who received rituximab had lower numbers of infections, hospital admissions, and emergency department visits per year after initiating rituximab.
Between the patients receiving conventional treatment alone and those receiving rituximab, there was no difference in the likelihood of complete remission, but those who received rituximab gained remission in a median time period of 6 months, while those who received conventional treatments gained remission after a median of 10.7 months.
“Rituximab may facilitate remission by a different, more efficient mechanism compared to [conventional therapy] as it decreased prednisone intake dramatically and significantly in the [rituximab] group despite their more severe disease,” write the authors, who add that even those who respond well to conventional drugs may benefit from earlier intervention with rituximab in terms of fewer infections, hospitalizations, laboratory draws, and clinic visits.
Reference
AgarwalA, Hall RP, Bañez LL, Cardones AR. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis [published online September 25, 2018]. PLOS One. https://doi.org/10.1371/journal.pone.0198074.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.